Evidence map›Paper›PMID 24319083›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014

Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada.

Maile Y Karris, Susan E Beekmann, Sanjay R Mehta, Christy M Anderson, Philip M Polgreen

Registry-linked trialAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03617874 (PC4PrEP), which is not on this map. Cited by 129 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03617874 nacompletednot on this mapstarted 2020, after this paper: background citation

PC4PrEP: Integrating Pre-Exposure Prophylaxis (PrEP) Into Primary Care

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2020 to 2022Enrolled22ConditionsHuman Immunodeficiency Virus TransmissionArmsPC4PrEP- Intervention Clinics, Standard of Care Clinics
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017
    Guideline
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Knowledge and attitudes of HIV pre-exposure prophylaxis among nurses in South Africa.African journal of primary health care & family medicine · 2023
    Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Maile Y KarrisDepartment of Internal Medicine, University of California San Diego, La Jolla.
Susan E Beekmann
Sanjay R Mehta
Christy M Anderson
Philip M Polgreen

Funding

San Diego Clinical and Translational Research InstituteKL2TR000099 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2014
$1.1M
Molecular Epidemiology of HIV-1 in the California-Mexico Border RegionK23AI093163 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MEHTA, SANJAY R · 2011 to 2015
$643k
San Diego Clinical and Translational Research InstituteKL2RR031978 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2010 to 2011
$615k
NCATS NIH HHS KL2 TR000099NCATS NIH HHS KL2TR00099NCEZID CDC HHS 5U50CK000187NCEZID CDC HHS U50 CK000187NCRR NIH HHS KL2 RR031978NIAID NIH HHS K23 AI093163
6 · The paper itself

Abstract

backgroundPreexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada) has demonstrated efficacy in placebo-controlled clinical trials involving men who have sex with men, high-risk heterosexuals, serodiscordant couples, and intravenous drug users. To assist in the real-world provision of PrEP, the Centers for Disease Control and Prevention (CDC) has released guidance documents for PrEP use.

methodsAdult infectious disease physicians were surveyed about their opinions and current practices of PrEP through the Emerging Infections Network (EIN). Geographic information systems analysis was used to map out provider responses across the United States.

resultsOf 1175 EIN members across the country, 573 (48.8%) responded to the survey. A majority of clinicians supported PrEP but only 9% had actually provided it. Despite CDC guidance, PrEP practices were variable and clinicians reported many barriers to its real-world provision.

conclusionsThe majority of adult infectious disease physicians across the United States and Canada support PrEP but have vast differences of opinion and practice, despite the existence of CDC guidance documents. The success of real-world PrEP will likely require multifaceted programs addressing barriers to its provision and will be assisted with the development of comprehensive guidelines for real-world PrEP.

Indexed as

AdultAnti-HIV AgentsCanadaChemopreventionDeoxycytidineDisease Transmission, InfectiousDrug CombinationsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIV InfectionsHumansMaleOrganophosphorus CompoundsPre-Exposure ProphylaxisUnited StatesAnti-HIV AgentsDeoxycytidineDrug CombinationsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationOrganophosphorus CompoundsHIVPrEPproviderssurvey

Identifiers

PMID24319083
PMCPMC3922214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.